Genevant Sciences
James Heyes has served as Chief Scientific Officer of Genevant Sciences Corporation since July 2020. Previously, he was Senior Vice President, Technology Development from Genevant’s inception in April 2018. Prior to joining Genevant, James was Vice President, Drug Delivery of Arbutus Biopharma. He brings over 20 years of experience in lipid chemistry and nucleic acid drug delivery and is an inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. James designed the lipid components enabling the first demonstration of RNA interference in primates and the advancement of 13 clinical candidates. He holds a PhD in Medicinal and Pharmaceutical Chemistry from the University of London and a BS in Chemistry from the University of Manchester.
This person is not in any offices
Genevant Sciences
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. They leverage world-class delivery systems and related technologies to bring new medicines to patients who need them. Genevant does this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows them to maintain our leadership position in the space.